

References for (1→3)-β-D-Glucan Assay

Clinical Practice Guidelines

1. Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., Evans, L., Gershengorn, H. B., Hodgson, C. L., Honarmand, K., Kesecioglu, J., McIntyre, L., Mer, M., Nunnally, M. E., Oczkowski, S. J. W., ... Coopersmith, C. M. (2026). **Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2026**. *Intensive Care Medicine*, 52(5), 863–936. <https://doi.org/10.1007/s00134-026-08361-1>
2. Schelenz, S., Abdolrasouli, A., Armstrong-James, D., Ashbee, H. R., Barton, R., Bicanic, T., Borman, A., Brown, L., Eades, C., Ferreras-Antolin, L., Gorton, R., McMullan, R., Page, I., Perera, N., Rautemaa-Richardson, R., Wagener, J., Lewis White, P., & Denning, D. W. (2026). **British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update**. *The Lancet. Infectious diseases*, 26(6), e217–e231. [https://doi.org/10.1016/S1473-3099\(25\)00550-X](https://doi.org/10.1016/S1473-3099(25)00550-X)
3. Cornely, O. A., Sprute, R., Bassetti, M., Chen, S. C., Groll, A. H., Kurzai, O., Lass-Flörl, C., Ostrosky-Zeichner, L., Rautemaa-Richardson, R., Revathi, G., Santolaya, M. E., White, P. L., Alastruey-Izquierdo, A., Arendrup, M. C., Baddley, J., Barac, A., Ben-Ami, R., Brink, A. J., Grothe, J. H., Guinea, J., ... Zhu, L. P. (2025). **Global guideline for the diagnosis and management of candidiasis: An initiative of the ECMM in cooperation with ISHAM and ASM**. *The Lancet Infectious Diseases*, 25(5), e280–e293. [https://doi.org/10.1016/S1473-3099\(24\)00749-7](https://doi.org/10.1016/S1473-3099(24)00749-7)
4. Wichmann, D., Hoenigl, M., Koehler, P., Koenig, C., Lund, F., Mang, S., Strauß, R., Weigand, M. A., Hohmann, C., Kurzai, O., Heußel, C., & Kochanek, M. (2025). **Diagnosis and treatment of invasive pulmonary aspergillosis in critically ill intensive care patients: Executive summary of the German national guideline (AWMF 113-005)**. *Infection*, 53(4), 1299–1310. <https://doi.org/10.1007/s15010-025-02572-2>
5. Brunkhorst, F. M., Adamzik, M., Axer, H., Bauer, M., Bode, C., Bone, H.-G., Brenner, T., Bucher, M., David, S., Dietrich, M., Eckmann, C., Elke, G., Esser, T., Felbinger, T., Geffers, C., Gerlach, H., Grabein, B., Gründling, M., Günther, U., ... Zarbock, A. (2025). **S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge – Update 2025**. *Medizinische Klinik - Intensivmedizin und Notfallmedizin*, 120(S2), 163–231. <https://doi.org/10.1007/s00063-025-01317-1>
6. Sandherr, M., Stemler, J., Schalk, E., Hattenhauer, T., Hentrich, M., Hertenstein, B., Hohmann, C., Mellinshoff, S. C., Mispelbaum, R., Rieger, C., Schmidt-Hieber, M., Sprute, R., Weiss, G., Cornely, O. A., Henze, L., Lass-Flörl, C., Beutel, G., Classen, A. Y., Freise, N. F., ... Busch, E. (2025). **2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies**. *The Lancet Regional Health—Europe*, 51, 101214. <https://doi.org/10.1016/j.lanepe.2025.101214>
7. Maseda, E., Peláez, T., Aguilar, G., Martín-Loeches, I., Benítez-Cano, A., Rodríguez, A., Zaragoza, R., Guinea, J., Aldecoa, C., & Suárez-de-la-Rica, A. (2025). **Expert opinion-based recommendations promoted by GTIPO-SEDAR to optimize the therapeutic management of intra-abdominal candidiasis**. *Revista Española de Anestesiología y Reanimación (English Edition)*, 72(9), 501916. <https://doi.org/10.1016/j.redare.2025.501916>
8. Miller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gonzalez, M. D., Harrington, A., Jerris, R. C., Kehl, S. C., Leal, S. M., Patel, R., Pritt, B. S., Richter, S. S., Robinson-Dunn, B., Snyder, J. W., Telford, S., Theel, E. S., Thomson, R. B., Weinstein, M. P., & Yao, J. D. (2024). **Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2024 update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)**. *Clinical Infectious Diseases*, Article ciae104. <https://doi.org/10.1093/cid/ciae104>
9. Bupha-Intr, O., Butters, C., Reynolds, G., Kennedy, K., Meyer, W., Patil, S., Bryant, P., Morrissey, C.O. and Australasian Antifungal Guidelines Steering Committee (2021), **Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology/oncology setting**, 2021. *Intern Med J*, 51: 177-219. <https://doi.org/10.1111/imj.15592>
10. Donnelly, J. P., Chen, S. C., Kauffman, C. A., Steinbach, W. J., Baddley, J. W., Verweij, P. E., Clancy, C. J., Wingard, J. R., Lockhart, S. R., Groll, A. H., Sorrell, T. C., Bassetti, M., Akan, H., Alexander, B. D., Andes, D., Azoulay, E., Bialek, R., Bradsher, R. W., Bretagne, S., ... Pappas, P. G. (2020). **Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium**. *Clinical Infectious Diseases*, 71(6), 1367–1376. <https://doi.org/10.1093/cid/ciz1008>

11. Koehler, P., Bassetti, M., Chakrabarti, A., Chen, S. C. A., Colombo, A. L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R. O., Vinh, D. C., Zhu, L.-P., Böll, B., Brüggemann, R., Gangneux, J.-P., Perfect, J. R., Patterson, T. F., Persigehl, T., Meis, J. F., Ostrosky-Zeichner, L., ... Cornely, O. A. (2021). **Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.** *The Lancet Infectious Diseases*, 21(6), e149–e162. [https://doi.org/10.1016/S1473-3099\(20\)30847-1](https://doi.org/10.1016/S1473-3099(20)30847-1)
12. Hage, C. A., Carmona, E. M., Epelbaum, O., Evans, S. E., Gabe, L. M., Haydour, Q., Knox, K. S., Kolls, J. K., Murad, M. H., Wengenack, N. L., & Limper, A. H. (2019). **Microbiological laboratory testing in the diagnosis of fungal infections in pulmonary and critical care practice: An official American Thoracic Society clinical practice guideline.** *American Journal of Respiratory and Critical Care Medicine*, 200(5), 535–550. <https://doi.org/10.1164/rccm.201906-1185ST>
13. Warris, A., Lehnbecher, T., Roilides, E., Castagnola, E., Brüggemann, R. J. M., & Groll, A. H. (2019). **ESCMID-ECMM guideline: Diagnosis and management of invasive aspergillosis in neonates and children.** *Clinical Microbiology and Infection*, 25(9), 1096–1113. <https://doi.org/10.1016/j.cmi.2019.05.019>
14. Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., Warris, A., Ader, F., Akova, M., Arendrup, M. C., Barnes, R. A., Beigelman-Aubry, C., Blot, S., Bouza, E., Brüggemann, R. J. M., ... Cornely, O. A. (2018). **Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline.** *Clinical Microbiology and Infection*, 24(Suppl. 1), e1–e38. <https://doi.org/10.1016/j.cmi.2018.01.002>
15. Ruhnke, M., Behre, G., Buchheidt, D., Christopeit, M., Hamprecht, A., Heinz, W., Heussel, C., Horger, M., Kurzai, O., Karthaus, M., Löffler, J., Maschmeyer, G., Penack, O., Rieger, C., Rickerts, V., Ritter, J., Schmidt-Hieber, M., Schuelper, N., Schwartz, S., ... Wolf, H. H. (2018). **Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO).** *Mycoses*, 61(11), 796–813. <https://doi.org/10.1111/myc.12838>

Review Articles

16. Vanbiervliet, Y., Aerts, R., Maessen, L., Wauters, J., Maertens, J., & Lagrou, K. (2026). **Laboratory innovations to diagnose invasive mould infections—What is relevant, what is not?** *Clinical Microbiology and Infection*, 32(5), 715–728. <https://doi.org/10.1016/j.cmi.2025.10.017>
17. Lass-Flörl, C. (2025). **Beyond guidelines: What do I need to know when dealing with fungal diagnostics?** *Clinical Microbiology and Infection*, 31(12), 1980–1984. <https://doi.org/10.1016/j.cmi.2025.07.016>
18. Cabrera-Guerrero, J. P., García-Salazar, E., Hernandez Silva, G., Chinney Herrera, A., Martínez-Herrera, E., Pinto-Almazán, R., Frías-De-León, M. G., & Castro-Fuentes, C. A. (2025). **Candidemia: An update on epidemiology, risk factors, diagnosis, susceptibility, and treatment.** *Pathogens*, 14(8), Article 806. <https://doi.org/10.3390/pathogens14080806>
19. Morjaria, S., & Babady, N. E. (2025). **Maximizing the diagnostic potential of 1,3-beta-D-glucan assays for invasive fungal infections.** *Clinical Microbiology Newsletter*, 50, 24–33. <https://doi.org/10.1016/j.clinmicnews.2025.01.001>
20. Sabino, R., Antunes, F., Araujo, R., Bezerra, A. R., Brandão, J., Carneiro, C., Carvalho, A., Carvalho, D., Conceição, I. C., Cota Medeiros, F., Cruz, C., Duarte, E., Holum, S., Matos, O., Maltez, F., Mendonça, A., Moura, G., Pereira, A., Fortuna Rodrigues, C., Teixeira, P., ... Portuguese Association of Medical Mycology (ASPOMM). (2025). **Addressing critical fungal pathogens under a One Health perspective: Key insights from the Portuguese Association of Medical Mycology.** *Mycopathologia*, 190(5), Article 73. <https://doi.org/10.1007/s11046-025-00981-3>
21. Ghaly Elmasry, W., Mohamed Abdelbaky, A., & Ahmed Awad, A. H. (2025). **Management of invasive candidiasis in the ICU: Challenges and advances (Review).** *Medicine International*, 5(6), 1–9. <https://doi.org/10.3892/mi.2025.278>
22. Gressens, S. B., Rouzaud, C., Lamoth, F., Calandra, T., Lanternier, F., & Lortholary, O. (2025). **Duration of systemic antifungal therapy for patients with invasive fungal diseases: A reassessment.** *Molecular Aspects of Medicine*, 103, 101347. <https://doi.org/10.1016/j.mam.2025.101347>
23. Sedik, S., Wolfgruber, S., Hoenigl, M., & Kriegl, L. (2024). **Diagnosing fungal infections in clinical practice: A narrative review.** *Expert Review of Anti-Infective Therapy*, 22(11), 935–949. <https://doi.org/10.1080/14787210.2024.2403017>
24. Casalini, G., Giacomelli, A., & Antinori, S. (2024). **The WHO fungal priority pathogens list: A crucial reappraisal to review the prioritisation.** *The Lancet Microbe*, 5, 717–724. [https://doi.org/10.1016/S2666-5247\(24\)00042-9](https://doi.org/10.1016/S2666-5247(24)00042-9)

25. Salmanton-García, J., Hoenigl, M., Gangneux, J. P., Segal, E., Alastruey-Izquierdo, A., Arikan Akdagli, S., Lagrou, K., Özenci, V., Vena, A., & Cornely, O. A. (2023). **The current state of laboratory mycology and access to antifungal treatment in Europe: A European Confederation of Medical Mycology survey.** *The Lancet Microbe*, 4(1), e47–e56. [https://doi.org/10.1016/S2666-5247\(22\)00261-0](https://doi.org/10.1016/S2666-5247(22)00261-0)
26. White, P. L. (2023). **Developments in fungal serology.** *Current Fungal Infection Reports*, 1–12. Advance online publication. <https://doi.org/10.1007/s12281-023-00462-4>
27. World Health Organization. (2022). **WHO fungal priority pathogens list to guide research, development and public health action.** <https://www.who.int/publications/i/item/9789240060241>
28. Barantsevich, N., & Barantsevich, E. (2022). **Diagnosis and treatment of invasive candidiasis.** *Antibiotics*, 11(6), Article 718. <https://doi.org/10.3390/antibiotics11060718>
29. Giacobbe, D. R., Asperges, E., Cortegiani, A., Grecchi, C., Rebuffi, C., Zuccaro, V., Scudeller, L., Bassetti, M., & FUNDICU investigators (2022). **Performance of existing clinical scores and laboratory tests for the diagnosis of invasive candidiasis in critically ill, nonneutropenic, adult patients: A systematic review with qualitative evidence synthesis.** *Mycoses*, 65(12), 1073–1111. <https://doi.org/10.1111/myc.13515>
30. Driemeyer, C., Falci, D. R., Hoenigl, M., Cornely, O. A., Chakrabarti, A., Gangneux, J. P., Segal, E., Jürna- Ellam, M., Matos, T., Meis, J. F., Perfect, J. R., Arsenijevic, V. A., Mares, M., Serban, D. E., & Pasqualotto, A. C. (2022). **The current state of clinical mycology in Eastern and South-Eastern Europe.** *Medical Mycology*, 60(4), Article myac017. <https://doi.org/10.1093/mmy/myac017>
31. Mendonça, A., Santos, H., Franco-Duarte, R., & Sampaio, P. (2022). **Fungal infections diagnosis—Past, present and future.** *Research in Microbiology*, 173(3), Article 103915. <https://doi.org/10.1016/j.resmic.2021.103915>
32. Lamoth, F., Akan, H., Andes, D., Cruciani, M., Marchetti, O., Ostrosky-Zeichner, L., Racil, Z., & Clancy, C. J. (2021). **Assessment of the role of 1,3-β-D-glucan testing for the diagnosis of invasive fungal infections in adults.** *Clinical Infectious Diseases*, 72(Suppl.2), S102– S108. <https://doi.org/10.1093/cid/ciaa1943>
33. Lass-Flörl, C., Samardzic, E., & Knoll, M. (2021). **Serology anno 2021—Fungal infections: From invasive to chronic.** *Clinical Microbiology and Infection*, 27(9), 1230–1241. <https://doi.org/10.1016/j.cmi.2021.02.005>
34. Mikulska, M., Balletto, E., Castagnola, E., & Mularoni, A. (2021). **Beta-D-glucan in patients with haematological malignancies.** *Journal of Fungi*, 7(12), Article 1046. <https://doi.org/10.3390/jof7121046>
35. Yoshida, M. (2021). **Development of a Method of Measuring β-D-Glucan and Its Use in Preemptive Therapy for Invasive Fungal Infections.** *International Journal of Molecular Sciences*, 22(17), 9265. <https://doi.org/10.3390/ijms22179265>
36. White, S. K., Schmidt, R. L., Walker, B. S., & Hanson, K. E. (2020). **(1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people.** *Cochrane Database of Systematic Reviews*, 7(7), Article CD009833. <https://doi.org/10.1002/14651858.CD009833.pub2>

Multicenter Studies

30. Akazawa, H., Fukushima, S., Higuchi, T., Miyoshi, T., Nakano, Y., Iio, K., Akamatsu, Y., Haruki, Y., Iwamoto, Y., Tanaka, S., Fujisato, S., Ako, S., & Hagiya, H. (2025). **Prognostic value of serum (1→3)-β-D-glucan levels in patients with candidemia stratified by compliance with Candida bundle: A multicenter retrospective cohort study (2016–2023).** *Mycopathologia*, 190(6), Article 90. <https://doi.org/10.1007/s11046-025-00999-7>
31. Fernandes, R., Sabino, R., Cunha, C., Cornely, O. A., Carvalho, A., Salmanton-García, J., & PT Group for IFI Management Capacity. (2024). **Multicentric study on the clinical mycology capacity and access to antifungal treatment in Portugal.** *Mycopathologia*, 189(1), Article 15. <https://doi.org/10.1007/s11046-024-00830-9>
32. Giacobbe, D. R., Dettori, S., Di Pilato, V., Asperges, E., Ball, L., Berti, E., Blennow, O., Bruzzzone, B., Calvet, L., Capra Marzani, F., Casabella, A., Choudaly, S., Dartel, A., De Pascale, G., Di Meco, G., Fallon, M., Galerneau, L. M., Gallego, M., Giacomini, M., González Sáez, A., Hänsel, L., Icardi, G., Koehler, P., Lagrou, K., Lahmer, T., Lewis White, P., Magnasco, L., Marchese, A., Marelli, C., Marín-Arriaza, M., Martin-Loeches, I., Mekontso-Dessap, A., Mikulska, M., Mularoni, A., Nordlander, A., Poissy, J., Russell, G., Signori, A., Tascini, C., Vaconsin, L. M., Vargas, J., Vena, A., Wauters, J., Pelosi, P., Timsit, J. F., & Bassetti, M. (2023). **Pneumocystis jirovecii pneumonia in intensive care units: A multicenter study by ESGCIP and EFISG.** *Critical Care*, 27(1), Article 323. <https://doi.org/10.1186/s13054-023-04608-1>
33. Novy, E., Rivière, J., Nguyen, M., Arfeuille, G., Louis, G., Bouhemad, B., Pottecher, J., Heektsweiler, S., Germain, A., Laithier, F. X., Losser, M. R., Debourgogne, A., Bernard, Y., Rousseau, H., Baumann, C., Luc, A., Birkener, J., Machouart, M. C., & Guerci, P. (2023). **Combination of serum and peritoneal 1.3-beta-D- glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: A multicenter prospective study.** *Critical Care*, 27(1), Article 470. <https://doi.org/10.1186/s13054-023-04761-7>

Laboratory Medicine/ Method Validation

34. Albanell-Fernández, M., Tuset, M., Vergara, A., Villanueva, M., Barrantes-González, M., Bodro, M., Soriano, A., Hernández-Meneses, M., Muñoz-Rojas, G., & Herrera, S. (2026). **Biomarker-driven strategy for early discontinuation of empirical antifungal treatment in critically ill patients: The role of (1-3)- β -D-glucan using Wako® test.** *Journal of Antimicrobial Chemotherapy*, 81(8), dkag226. <https://doi.org/10.1093/jac/dkag226>
35. Fernández-Ruiz, M., Pérez-Ayala, A., Castaño Amores, M. V., Del Nopal Labrador, F., Guevara Rodado, M. D. C., Pérez-Jacoiste Asín, M. A., Rodríguez-Goncer, I., Silva, J. T., Redondo, N., López-Medrano, F., San Juan, R., & Aguado, J. M. (2026). **False-positive results of the turbidimetric β -D-glucan assay in patients with bacteremia.** *Diagnostic Microbiology and Infectious Disease*, 114(3), Article 117186. <https://doi.org/10.1016/j.diagmicrobio.2025.117186>
36. Kinet-Poleur, A., Deckers, C., Saad Albichr, I., Bogaerts, P., Honoré, P. M., Bulpa, P., Ausselet, N., Foret, F., Kidd, F., Huang, T. D., & Montesinos, I. (2025). **Evaluation of serum biomarkers for improved diagnosis of candidemia.** *Journal of Fungi*, 11(3), Article 224. <https://doi.org/10.3390/jof11030224>
37. Oldberg, K., Stenmark, J., & Hammarström, H. (2025). **β -D-glucan testing in candidemia: Determinants of positivity and association with mortality.** *Mycoses*, 68(5), Article e70067. <https://doi.org/10.1111/myc.70067>
38. Samaddar, A., Supriya, M., Nagarathna, S., & Vinutha, S. (2025). **Evaluation of the Fujifilm Wako β -glucan assay in cerebrospinal fluid for the diagnosis of non-cryptococcal fungal infections of the central nervous system.** *Diagnostic Microbiology and Infectious Disease*, 113(4), Article 117071. <https://doi.org/10.1016/j.diagmicrobio.2025.117071>
39. Ullah, N., Muccio, M., Magnasco, L., Sepulcri, C., Giacobbe, D. R., Vena, A., Bassetti, M., & Mikulska, M. (2025). **Species-specific sensitivity and levels of beta-D-glucan for the diagnosis of candidemia: A systematic review and meta-analysis.** *Journal of Fungi*, 11(2), Article 149. <https://doi.org/10.3390/jof11020149>
40. Schub, T., Klugherz, I., Wagener, J., Prattes, J., Hoenigl, M., Suerbaum, S., Held, J., & Dichtl, K. (2024). **Serum antigen tests for the diagnosis of invasive aspergillosis: A retrospective comparison of five *Aspergillus* antigen assays and one beta-D-glucan assay.** *Journal of Clinical Microbiology*, 62(12), Article e00950-24. <https://doi.org/10.1128/jcm.00950-24>
41. Kritikos, A., Caruana, G., Poissy, J., Mamin, A., Bachmann, D., Pagani, J. L., Coste, A. T., & Lamoth, F. (2023). **Comparison of three β -glucan tests for the diagnosis of invasive candidiasis in intensive care units.** *Journal of Clinical Microbiology*, 61, Article e01691-22. <https://doi.org/10.1128/jcm.01691-22>
42. Lamoth, F., Nucci, M., Fernández-Cruz, A., Azoulay, E., Lanternier, F., Bremerich, J., Einsele, H., Johnson, E., Lehnbecher, T., Mercier, T., Porto, L., Verweij, P. E., White, L., Maertens, J., Alanio, A., & 9th European Conference on Infections in Leukemia (ECIL-9). (2023). **Performance of the beta-glucan test for the diagnosis of invasive fusariosis and scedosporiosis: A meta-analysis.** *Medical Mycology*, 61(7), Article myad061. <https://doi.org/10.1093/mmy/myad061>
43. Miyajima, Y., Nagaoka, K., Takegoshi, Y., Kaneda, M., Murai, Y., Kimoto, K., Kawamura, T., Ueno, A., Kawasuji, H., Kawago, K., Fukui, Y., Sakamaki, I., & Yamamoto, Y. (2023). **Comparative study of three commercial blood (1 $\rightarrow$ 3)- β -D-glucan detection reagents for invasive mycosis.** *Medical Mycology Journal*, 64(1), 1–6. <https://doi.org/10.3314/mmj.22-00016>
44. Singh, S., Kanaujia, R., Agnihotri, S., Kaur, H., Chakrabarti, A., & Rudramurthy, S. M. (2023). **The comparative evaluation of the Fujifilm Wako β -glucan assay and Fungitell assay for diagnosing invasive fungal disease.** *Journal of Fungi*, 9(1), Article 6. <https://doi.org/10.3390/jof9010006>
45. Forster, J., Dichtl, K., & Wagener, J. (2022). **Lower beta-1,3-D-glucan testing cut-offs increase sensitivity for non-*albicans* *Candida* species bloodstream infections.** *Mycoses*, 65(5), 500–507. <https://doi.org/10.1111/myc.13421>
46. Forster, J., Hoenigl, M., Suerbaum, S., Wagener, J., & Dichtl, J. (2022). **Serologic biomarkers in *Candida* and *Aspergillus* infections of the central nervous system: A comparison of galactomannan, mannan, and β -1,3-D-glucan testing from serum and cerebrospinal fluid.** *Mycoses*, 65(7), 709–714. <https://doi.org/10.1111/myc.13451>
47. Forster, J., Koc, Ö., Koepfel, M. B., Hamprecht, A., Kurzai, O., Suerbaum, S., Wagener, J., & Dichtl, K. (2022). **β -1,3-d-Glucan and Galactomannan as Biomarkers for the Detection of Invasive *Geotrichum* and *Magnusiomyces* Infections: a Retrospective Evaluation.** *Journal of clinical microbiology*, 60(1), e0160721. <https://doi.org/10.1128/JCM.01607-21>
48. Bamba, Y., Nagano, K., Moro, H., Ogata, H., Hakamata, M., Shibata, S., Koizumi, T., Aoki, N., Ohshima, Y., Watanabe, S., Nakamura, T., Kobayashi, S., Hoshiyama, Y., Koya, T., Takada, T., & Kikuchi, T. (2021). **Efficacy of the new β -D-glucan measurement kit for diagnosing invasive fungal infections, as compared with that of four conventional kits.** *PLOS ONE*, 16(8), Article e0255172. <https://doi.org/10.1371/journal.pone.0255172>

49. De Carolis, E., Marchionni, F., Torelli, R., Angela, M. G., Pagano, L., & Murri, R. (2020). **Comparative performance evaluation of Wako β -glucan test and Fungitell assay for the diagnosis of invasive fungal diseases.** *PLOS ONE*, 15(7), Article e0236095. <https://doi.org/10.1371/journal.pone.0236095>
50. Dichtl, K., Forster, J., Ormanns, S., Horns, H., Suerbaum, S., Seybold, U., & Wagener, J. (2020). **Comparison of β -D-glucan and galactomannan in serum for detection of invasive aspergillosis: Retrospective analysis with focus on early diagnosis.** *Journal of Fungi*, 6(4), Article 253. <https://doi.org/10.3390/jof6040253>
51. Mercier, T., Guldentops, E., Patteet, S., Beuselinck, K., Lagrou, K., & Maertens, J. (2019). **Beta- d -Glucan for Diagnosing Pneumocystis Pneumonia: A Direct Comparison between the Wako β -Glucan Assay and the Fungitell Assay.** *Journal of Clinical Microbiology*, 57(6), e00322-19. <https://doi.org/10.1128/JCM.00322-19>
52. Friedrich, R., Rappold, E., Bogdan, C., & Held, J. (2018). **Comparative analysis of the Wako β -glucan test and the Fungitell assay for diagnosis of candidemia and *Pneumocystis jirovecii* pneumonia.** *Journal of Clinical Microbiology*, 56(9), Article e00464-18. <https://doi.org/10.1128/JCM.00464-18>

ICU/ Critical Care

53. Vazquez, J. A., Whitaker, L., & Zubovskaia, A. (2025). **Invasive Candidiasis in the Intensive Care Unit: Where Are We Now?** *Journal of Fungi*, 11(4), 258. <https://doi.org/10.3390/jof11040258>
54. Noppè, E., Eloff, J. R. P., Keane, S., & Martin-Loeches, I. (2024). **A Narrative Review of Invasive Candidiasis in the Intensive Care Unit.** *Therapeutic Advances in Pulmonary and Critical Care Medicine*, 19, 29768675241304684. <https://doi.org/10.1177/29768675241304684>
55. Azim, A., & Ahmed, A. (2024). **Diagnosis and management of invasive fungal diseases in non-neutropenic ICU patients, with focus on candidiasis and aspergillosis: A comprehensive review.** *Frontiers in Cellular and Infection Microbiology*, 14, Article 1256158. <https://doi.org/10.3389/fcimb.2024.1256158>
56. Christner, M., Abdennadher, B., Wichmann, D., Kluge, S., Pepić, A., Aepfelbacher, M., Rohde, H., & Olearo, F. (2024). **The added value of (1,3)- β -D-glucan for the diagnosis of invasive candidiasis in ICU patients: A prospective cohort study.** *Infection*, 52(1), 73–81. <https://doi.org/10.1007/s15010-023-02053-4>
57. Kritikos, A., Caruana, G., Poissy, J., Mamin, A., Bachmann, D., Pagani, J. L., Coste, A. T., & Lamoth, F. (2023). **Comparison of three β -glucan tests for the diagnosis of invasive candidiasis in intensive care units.** *Journal of Clinical Microbiology*, 61, Article e01691-22. <https://doi.org/10.1128/jcm.01691-22>
58. Bassetti, M., Azoulay, E., Kullberg, B.-J., Ruhnke, M., Shoham, S., Vazquez, J., Giacobbe, D. R., & Calandra, T. (2021). **EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group.** *Clinical Infectious Diseases*, 72(Supplement_2), S121–S127. <https://doi.org/10.1093/cid/ciaa1751>
59. Aggarwal, A., & Chawla, M. P. S. (2021). **Diagnosis and management of invasive fungal infections in critical care setting.** *Journal of Indian Academy of Clinical Medicine*, 22(3–4), 117–132. https://www.jiacm.in/2021/Journal_79_Final_Page_117_132.pdf
60. De Pascale, G., Posteraro, B., D'Arrigo, S., Spinazzola, G., Gaspari, R., Bello, G., ... & Antonelli, M. (2020). **(1, 3)- β -d- Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial.** *Critical Care*, 24(1), 550. <https://doi.org/10.1186/s13054-020-03265-y>
61. Cento, V., Alteri, C., Mancini, V., Gatti, M., Lepera, V., Mazza, E., Moiola, M. C., Merli, M., Colombo, J., Orcese, C. A., Bielli, A., Torri, S., Gasparini, L. E., Vismara, C., De Gasperi, A., Brioschi, P., Puoti, M., Cairoli, R., Lombardi, G., & Perno, C. F. (2020). **Quantification of 1,3- β -D-glucan by Wako β -glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study.** *Mycoses*, 63(12), 1299–1310. <https://doi.org/10.1111/myc.13170>

Hematology/Oncology/ HSCT or Cellular Therapy

62. Gandolpho, L. S., Aguilar-Zapata, D., Moncada-Vallejo, P. A., Riera, F., Guaraná, M., Breda, G. L., Rabagliati, R., Nucci, M., & Colombo, A. L. (2026). **Managing Breakthrough Fungal Infections in Hematologic Patients: Determinants and Practical Management from a Latin American Perspective on Behalf of INFOCUS LATAM–ISHAM Working Group.** *Microorganisms*, 14(4), 904. <https://doi.org/10.3390/microorganisms14040904>

63. Reikvam, H., Tsykunova, G., Sandnes, M., & Wendelbo, Ø. (2025). **Infectious complications and the utility of serum and cellular markers of infections in the setting of allogeneic hematopoietic stem cell transplantation.** *Expert Review of Clinical Immunology*, 21(3), 291–303. <https://doi.org/10.1080/1744666X.2025.2450014>
64. Flett, L., Abdelatif, R., Baz, S. A., Brady, S., Corbacho, B., Common, K., Cowling, A., Fairhurst, C., Fitzmaurice, E., Gandhi, S., Hilton, A., Hope, W., Howard, A., Laycock, J., Lillie, P., Mitchell, G., Parker, A., Peel, M., Sheard, L., ... Barlow, G. (2024). **Biomarker driven antifungal stewardship (BioDriveAFS) in acute leukaemia: A multicentre randomised controlled trial to assess clinical and cost effectiveness: A study protocol for a randomised controlled trial.** *Trials*, 25(1), Article 427. <https://doi.org/10.1186/s13063-024-08272-w>
65. Aydın Kurc, M., Günaydin, B., Akpınar, S., Safak, B., & Kiraz, N. (2024). **Invasive pulmonary aspergillosis evaluation in hematology patients: Three years results of tertiary hospital.** *Biomolecules and Biomedicine*, 25(4), 850–856. <https://doi.org/10.17305/bb.2024.10766>
66. Busca, A., Cinatti, N., Gill, J., Passera, R., Dellacasa, C. M., Giaccone, L., Dogliotti, I., Manetta, S., Corcione, S., & De Rosa, F.G. (2022). **Management of invasive fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation: The Turin experience.** *Frontiers in Cellular and Infection Microbiology*, 11, Article 805514. <https://doi.org/10.3389/fcimb.2021.805514>
67. Machado, M., Chamorro De Vega, E., Martínez-Jiménez, M. D. C., Rodríguez-González, C. G., Vena, A., Navarro, R., Zamora-Cintas, M. I., Agnelli, C., Olmedo, M., Galar, A., Guinea, J., Fernández-Cruz, A., Alonso, R., Bouza, E., Muñoz, P., & Valerio, M. (2021). **Utility of 1,3 β -D-Glucan Assay for Guidance in Antifungal Stewardship Programs for Oncologic Patients and Solid Organ Transplant Recipients.** *Journal of Fungi*, 7(1), 59. <https://doi.org/10.3390/jof7010059>
68. Song, J., Kim, S., Park, J., Park, Y., & Kim, H.-S. (2021). **Comparison of two β -D-glucan assays for detecting invasive fungal diseases in immunocompromised patients.** *Diagnostic Microbiology and Infectious Disease*, 101(1), 115415. <https://doi.org/10.1016/j.diagmicrobio.2021.115415>
69. Springer, J., Held, J., Mengoli, C., Schlegel, P. G., Gamon, F., Träger, J., Kurzai, O., Einsele, H., Loeffler, J., & Eyrich, M. (2021). **Diagnostic performance of (1 $\rightarrow$ 3)- β -D-glucan alone and in combination with *Aspergillus* PCR and galactomannan in serum of pediatric patients after allogeneic hematopoietic stem cell transplantation.** *Journal of Fungi*, 7(3), Article 238. <https://doi.org/10.3390/jof7030238>
70. Lanternier, F., Seidel, D., Pagano, L., Styczynski, J., Mikulska, M., Pulcini, C., Maertens, J., Munoz, P., Garcia-Vidal, C., Rijnders, B., Arendrup, M. C., Sabino, R., Verissimo, C., Gaustad, P., Klimko, N., Arian-Akdagli, S., Arsic, V., Barac, A., Skiada, A., ... Lortholary, O. (2020). **Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWP-EBMT, EORTC-IDG and SEIFEM survey.** *Mycoses*, 63(5), 420–429. <https://doi.org/10.1111/myc.13056>
71. Ruhnke, M., Behre, G., Buchheidt, D., Christopeit, M., Hamprecht, A., Heinz, W., Heussel, C., Horgner, M., Kurzai, O., Karthaus, M., Löffler, J., Maschmeyer, G., Penack, O., Rieger, C., Rickerts, V., Ritter, J., Schmidt-Hieber, M., Schuelper, N., Schwartz, S., ... Wolf, H. H. (2018). **Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO).** *Mycoses*, 61(11), 796–813. <https://doi.org/10.1111/myc.12838>

Pulmonology

72. Falcó-Roget, A., Albasanz-Puig, A., Pérez-González, A., Serradell, S., Guillén, A., Díaz-Lagares, C., Revilla, E., Los-Arcos, I., Len, Ò., Ruiz-Camps, I., & Martín-Gómez, M. T. (2026). **Combined serum (1,3)- β -D-glucan and oral wash PCR as a noninvasive diagnostic strategy for early detection of *Pneumocystis jirovecii* pneumonia: An observational retrospective study.** *Open Forum Infectious Diseases*, 13(2), Article ofag033. <https://doi.org/10.1093/ofid/ofag033>
73. Haensel, L., Sprute, R., Grothe, J., Robert-Gangneux, F., Gangneux, J.-P., Meis, J. F., Cornely, O. A., & Koehler, P. (2025). **The 2025 EQUAL *Pneumocystis* Score—An ECMM tool to measure QUALity in *Pneumocystis* pneumonia management.** *JAC-Antimicrobial Resistance*, 7(5), dlaf165. <https://doi.org/10.1093/jacamr/dlaf165>
74. Hatzl, S., Geiger, C., Kriegl, L., Reinisch, A., Wölfler, A., Apfalter, G., Keldorfer, M., Rödl, S., Hoenigl, M., Eller, P., & Krause, R. (2025). **Pulmonary coinfection of *Pneumocystis jirovecii* and *Aspergillus* species.** *Open Forum Infectious Diseases*, 12(2), Article ofaf018. <https://doi.org/10.1093/ofid/ofaf018>

75. Jakab, Á., Harmath, A., Tóth, Z., Majoros, L., Kónya, J., & Kovács, R. (2025). **Epidemiology and clinical relevance of *Pneumocystis jirovecii* in non-human immunodeficiency virus patients at a tertiary care center in Central Europe: A 3-year retrospective study.** *Journal of Clinical Medicine*, 14(8), Article 2820. <https://doi.org/10.3390/jcm14082820>
76. Maldonado-Barrueco, A., Sanz-González, C., Rubio-Mora, E., Quiles-Melero, I., & García-Rodríguez, J. (2025). **Evaluation and clinical impact of the combination of Wako® (1,3)-β-D-glucan in serum and RT-PCR in oral wash for *Pneumocystis jirovecii* infection diagnosis: A retrospective cohort study.** *Medical Mycology*, 63(10), Article myaf085. <https://doi.org/10.1093/mmy/myaf085>
77. Zhan, Y., He, G., Zhong, C., Yao, Y., Zhou, J., Li, T., & Zhou, H. (2025). **Clinical features of COVID-19-associated pulmonary aspergillosis: A multicenter, retrospective study.** *Clinical Respiratory Journal*, 19, Article e70048. <https://doi.org/10.1111/crj.70048>
78. Giacobbe, D. R., Dettori, S., Di Pilato, V., Asperges, E., Ball, L., Berti, E., Blennow, O., Bruzzzone, B., Calvet, L., Capra Marzani, F., Casabella, A., Choudaly, S., Dartel, A., De Pascale, G., Di Meco, G., Fallon, M., Galerneau, L.-M., Gallego, M., Giacomini, M., ... Bassetti, M. (2023). ***Pneumocystis jirovecii* pneumonia in intensive care units: A multicenter study by ESGIP and EFISG.** *Critical Care*, 27(1), Article 323. <https://doi.org/10.1186/s13054-023-04608-1>
79. Fishman, J. A. (2020). ***Pneumocystis jirovecii*.** *Seminars in Respiratory and Critical Care Medicine*, 41(1), 141–157. <https://doi.org/10.1055/s-0039-3399559>
80. Mercier, T., Guldentops, E., Patteet, S., Beuselinck, K., Lagrou, K., & Maertens, J. (2019). **Beta-D-glucan for diagnosing *Pneumocystis* pneumonia: A direct comparison between the Wako β-glucan assay and the Fungitell assay.** *Journal of Clinical Microbiology*, 57(6), Article e00322-19. <https://doi.org/10.1128/JCM.00322-19>

Surgery/Abdominal Disease

81. Novy, E., Schaeffer, A., Nguyen, M., Dalle, F., Pottecher, J., Letscher-Bru, V., Louis, G., Stephan, C., Luc, A., Machouart, M., & Debourgogne, A. (2026). **Analytical performance of species-targeted quantitative PCR for intra-abdominal candidiasis in critically ill patients: A proof-of-concept post hoc analysis from the pBDG2 multicenter study.** *Critical Care*, 30(1), Article 117. <https://doi.org/10.1186/s13054-026-05882-5>
82. Novy, E., Esposito, M., Debourgogne, A., & Roger, C. (2025). **Reevaluating the value of (1,3)-β-D-glucan for the diagnosis of intra-abdominal candidiasis in critically ill patients: Current evidence and future directions.** *Journal of Fungi*, 11(2), Article 91. <https://doi.org/10.3390/jof11020091>
83. Novy, E., Rivière, J., Nguyen, M., Arfeuille, G., Louis, G., Bouhemad, B., Pottecher, J., Heeketsweiler, S., Germain, A., Laithier, F. X., Losser, M. R., Debourgogne, A., Bernard, Y., Rousseau, H., Baumann, C., Luc, A., Birkener, J., Machouart, M. C., & Guerci, P. (2023). **Combination of serum and peritoneal 1,3-beta-D-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: A multicenter prospective study.** *Critical Care*, 27(1), Article 470. <https://doi.org/10.1186/s13054-023-04761-7>
84. Novy, E., Laithier, F.-X., Riviere, J., Remen, T., Losser, M.-R., Guerci, P., & Machouart, M. (2021). **Protocol for the pBDG2 study: Prospective evaluation of 1,3-β-D-glucan in the peritoneal fluid for the diagnosis of intra-abdominal candidiasis in critically ill patients.** *Microbiology Research*, 12(1), 196–203. <https://doi.org/10.3390/microbiolres12010015>
85. Fortún, J., Buitrago, M. J., Gioia, F., Gómez-G^a de la Pedrosa, E., Alvarez, M. E., Martín-Dávila, P., Pintado, V., Cobeta, P., Martínez-Castro, N., Soriano, C., Moreno, I., Corral, S., Muñoz, P., Moreno-Jimenez, G., Cuenca-Estrella, M., & Moreno-Guillen, S. (2020). **Roles of the multiplex real-time PCR assay and β-D-glucan in a high-risk population for intra-abdominal candidiasis (IAC).** *Medical mycology*, 58(6), 789–796. <https://doi.org/10.1093/mmy/myz123>